Now that the political climate lends itself to action on drug pricing, the days of pharma nirvana may be coming to an end. Here’s a look at the policy considerations likely to vex the industry in the year ahead.
Newmark said she is prioritizing working with industry stakeholders on verification and validation standards.
Sen. Christopher Coons (D-DE) talked healthcare priorities at the Coalition for Healthcare Communication post-election conference in Washington D.C. on Monday.
With greater transparency of the cost and sale price of a drug must also come greater transparency of the inputs, ecosystem, and risk investment on which drug development relies.
The pharma industry is set for a battle as the Trump administration and trade group PhRMA offer competing solutions to putting drug prices in TV ads.
Boyd has worked at AbbVie, Pfizer, and Schering-Plough.
MM&M asked experts to predict what the next two years could hold for pharma- and healthcare-related legislation.
The Trump administration has proposed basing Medicare Part B drug prices on what other countries pay.
PhRMA pushed back on the HHS plan for disclosing drug prices in ads, putting itself in Trump’s Twitter crosshairs, but experts say flaws in the plan could impede its rollout anyway.
The FDA wants to know what’s the ideal context for risk info. Some experts assert that the question misses the point.
Please login or register first to view this content.
